Eli Lilly and Company (LLY)
| Market Cap | 784.71B |
| Revenue (ttm) | 45.04B |
| Net Income (ttm) | 10.59B |
| Shares Out | 898.17M |
| EPS (ttm) | 11.71 |
| PE Ratio | 74.61 |
| Forward PE | 37.82 |
| Dividend | $6.00 (0.69%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 3,909,276 |
| Open | 880.62 |
| Previous Close | 873.12 |
| Day's Range | 873.50 - 894.40 |
| 52-Week Range | 711.40 - 972.53 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 985.00 (+12.74%) |
| Earnings Date | Feb 6, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the comp... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $985.0, which is an increase of 12.74% from the latest price.
News
Eli Lilly's Breakout Is Nearly Here: Performance Metrics/Bullish Support Remain Robust
LLY's stock is attractively valued with high double digits capital appreciation prospects, driven by its promising GLP-1 therapies/ pipelines. Combined with the growing capacities and double digits gr...
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial stat...
Lilly's Chief Scientific Officer: 'We have an obligation to go after big problems'
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.
Lilly's Chief Scientific Officer has big plans for the next generation of weight loss drugs
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the compa...
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more potent ...
Lilly to participate in TD Cowen's 45th Annual Health Care Conference
INDIANAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice pres...
Top 5 growth stocks to watch in 2025 as market momentum builds
While concerns about a potential US recession persist, growth stocks have continued to outperform value stocks in 2024. Investors remain optimistic that the Federal Reserve's expected interest rate cu...
Calls of the Day: Live Nation, Eli Lilly, AT&T, Adobe and Astera Labs
The Investment Committee discuss the latest Calls of the Day.
Kenai Therapeutics Establishes Research Facility at Lilly Gateway Labs
SAN DIEGO--(BUSINESS WIRE)--Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacemen...
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
BRISBANE, Australia & INDIANAPOLIS--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and bre...
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
SEONGNAM, South Korea--(BUSINESS WIRE)-- #CardiometabolicIndications--OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX's OLX75016.
23 Upcoming Dividend Increases, Including 2 Kings
Excited to announce dividend hikes for 23 companies, including dividend kings SJW Group and California Water Service Group, with 5% and 7.1% increases. Companies with consistent dividend growth indica...
Buy, Sell, Or Hold LLY Stock At $870?
Eli Lilly (NYSE: LLY) fourth-quarter performance exceeded the street expectations, with the company delivering adjusted earnings of $5.32 per share versus the projected $4.95. Revenue came in at $13.5...
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one ye...
Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America's health focus across obesity and be...
Eli Lilly climbs after earnings, top analyst talks what's next for pharma giant
David Risinger, Leerink Partners, joins 'Fast Money' to talk Eli Lilly earnings.
Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight
Eli Lilly and Company's Q4 and full-year earnings showcased impressive growth, driven by tirzepatide's success, leading to a 45% revenue increase in Q4 and 32% for the year. Tirzepatide, marketed as M...
Eli Lilly and Company (LLY) Q4 2024 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY) Q4 2024 Results Conference Call February 6, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations David Ricks - Chair and CE...
Why did Eli Lilly report mixed Q4 results despite soaring demand for Zepbound and Mounjaro?
Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and diab...
Eli Lilly Stock Rises After Profit, Outlook Top Expectations
Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.
LLY Gains on Weight Loss Drugs, F Tariff Fears, HON Split
Eli Lilly (LLY) shares ran higher following its earnings report with its weight loss drugs in focus. Ford Motor Co. (F) hit a 52-week low with tariffs from President Trump posing questions around the ...
Novo, Lilly still leaders in obesity drug development: Barclays
Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity drug market.
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
On Thursday, Eli Lilly and Co LLY stock is trading higher after the company released better-than-expected fourth-quarter earnings and provided 2025 guidance.